Literature DB >> 24698192

The Clinical Practice Research Datalink for drug safety in pregnancy research: an overview.

Rachel Charlton, Julia Snowball, Cormac Sammon, Corinne de Vries.   

Abstract

Medicine use during pregnancy is common; however the safety of medicine use during pregnancy is largely unknown when a medicine comes to market. Electronic healthcare databases, including the Clinical Practice Research Datalink (CPRD), are increasingly being used for post-marketing surveillance in this field. The CPRD contains anonymised, longitudinal medical records routinely collected in primary care. Using CPRD data it is possible to identify medical records indicative of pregnancy, including pregnancy losses. Data on prescriptions issued can be used to determine maternal exposure and for about 80% of pregnancies it is possible to link the mother's medical record to the medical record of the child. Data in the medical records of the mother and child can then be used to identify adverse pregnancy outcomes, including congenital malformations. This paper describes some of the complexities involved in using CPRD data for pregnancy related research and discusses some of its strengths and limitations.
© 2014 Société Française de Pharmacologie et de Thérapeutique.

Entities:  

Mesh:

Year:  2014        PMID: 24698192     DOI: 10.2515/therapie/2014007

Source DB:  PubMed          Journal:  Therapie        ISSN: 0040-5957            Impact factor:   2.070


  6 in total

1.  Long term impact of prophylactic antibiotic use before incision versus after cord clamping on children born by caesarean section: longitudinal study of UK electronic health records.

Authors:  Dana Šumilo; Krishnarajah Nirantharakumar; Brian H Willis; Gavin M Rudge; James Martin; Krishna Gokhale; Rasiah Thayakaran; Nicola J Adderley; Joht Singh Chandan; Kelvin Okoth; Isobel M Harris; Ruth Hewston; Magdalena Skrybant; Jonathan J Deeks; Peter Brocklehurst
Journal:  BMJ       Date:  2022-05-17

Review 2.  COVID-19 in pregnancy-what study designs can we use to assess the risk of congenital anomalies in relation to COVID-19 disease, treatment and vaccination?

Authors:  Helen Dolk; Christine Damase-Michel; Joan K Morris; Maria Loane
Journal:  Paediatr Perinat Epidemiol       Date:  2022-03-02       Impact factor: 3.103

3.  Women's beliefs about medication use during their pregnancy: a UK perspective.

Authors:  M J Twigg; A Lupattelli; H Nordeng
Journal:  Int J Clin Pharm       Date:  2016-05-30

4.  Sensitivity of the UK Clinical Practice Research Datalink to Detect Neurodevelopmental Effects of Medicine Exposure in Utero: Comparative Analysis of an Antiepileptic Drug-Exposed Cohort.

Authors:  R A Charlton; A McGrogan; J Snowball; L M Yates; A Wood; J Clayton-Smith; W H Smithson; J L Richardson; N McHugh; S H L Thomas; G A Baker; R Bromley
Journal:  Drug Saf       Date:  2017-05       Impact factor: 5.606

5.  Long-term impact of giving antibiotics before skin incision versus after cord clamping on children born by caesarean section: protocol for a longitudinal study based on UK electronic health records.

Authors:  Dana Šumilo; Krishnarajah Nirantharakumar; Brian H Willis; Gavin Rudge; James Martin; Krishna Gokhale; Rasiah Thayakaran; Nicola J Adderley; Joht Singh Chandan; Kelvin Okoth; Ruth Hewston; Magdalena Skrybant; Jonathan J Deeks; Peter Brocklehurst
Journal:  BMJ Open       Date:  2019-09-26       Impact factor: 2.692

6.  Electronic Health Record-Triggered Research Infrastructure Combining Real-world Electronic Health Record Data and Patient-Reported Outcomes to Detect Benefits, Risks, and Impact of Medication: Development Study.

Authors:  Karin Hek; Leàn Rolfes; Eugène P van Puijenbroek; Linda E Flinterman; Saskia Vorstenbosch; Liset van Dijk; Robert A Verheij
Journal:  JMIR Med Inform       Date:  2022-03-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.